RxDoctor Payments DataLook up a doctor →

Carmel Joseph, MD

Pulmonary Disease · Augusta, GANPI 1245286681

Payments from drug & device makers

$42,836in general payments, 2019–2025

Across 1,045 payments — averaging $40.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$19K
  • Intuitive Surgical$5K
  • GSK$3K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Harmony Biosciences LLC$1K
  • plus $11K from 51 others

What the payments were for

  • Speaking & faculty fees$15,40036%
  • Travel & lodging$2,1575%
  • Food & beverage$21,79451%
  • Education$3,4868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,836 in reported general payments places this provider in the 85th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$315,260
Medicare patients
688
Services billed
4,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan96$1,210,024
UptraviSelexipag32$555,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter706$524,162
AdempasRiociguat34$490,276
OfevNintedanib Esylate32$367,654
Prolastin CAlpha-1-Proteinase Inhibitor20$201,944
WakixPitolisant Hcl12$182,560
Breztri AerosphereBudesonide/Glycopyr/Formoterol224$169,415
ZemairaAlpha-1-Proteinase Inhibitor13$126,288
Ambrisentan44$115,780
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$67,925
Breo ElliptaFluticasone/Vilanterol112$55,833
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$46,949
Spiriva RespimatTiotropium Bromide58$45,054
SymbicortBudesonide/Formoterol Fumarate93$37,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$2,011$1,765,196128 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,001$626,945897 claims
BayerAdempas$566$490,27634 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,103$468,980180 claims
AstraZenecaBreztri Aerosphere, Symbicort$19,342$206,737317 claims
Grifols USA, LLCProlastin C$362$201,94420 claims
CSL BehringZemaira, Hizentra$17$194,21326 claims
Harmony Biosciences LLCWakix$1,321$182,56012 claims
MerckDulera$508$3,90311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →